Answers are grounded in this paper and cite their sources.
This research reveals the benefits of MRD testing in managing early-stage breast cancer, suggesting implications for treatment strategies.
MRD testing in early-stage breast cancer theoretically confers a significant clinical benefit with adjuvant therapy and during patient surveillance. However, there are concerns with the potential for aggressive or prolonged treatment, not to mention the specific approach to managing patients who are ctDNA positive but remain asymptomatic.
No takes yet. Share an insight, caveat, or question.
Micha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: